T-DXd Plus THP Bolsters Pathologic Responses in Early-Stage Breast Cancer
Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.
Related Articles
Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC
Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.
Ascertaining AI’s Role in Cancer Diagnosis and Treatment
In this special edition episode, CancerNetwork® spoke with Viviana Cortiana, MS4, medical student at the Department of Medical and Surgical Sciences at the U…
Cemsidomide Combo May Produce Responses in Multiple Myeloma
Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.
FDA Gives Fast-Track Designation to ISB 2001 in Relapsed/Refractory Myeloma
Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.
Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer
Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.
Workplace Burnout Among Oncologists Has Risen: What Can Be Done?
Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them…
Concurrent Chemoradiation May Improve LS-SCLC Prognosis
Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.
Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma
No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.
Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma
No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.
Perseverance Underscores Success in Rare Lymphoma Research
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.